According to a 2013 study, both medications provided similar A1C-lowering efficacy in people with type 2 diabetes mellitus and chronic renal insufficiency. However, sitagliptin (Januvia) was generally well-tolerated, with a lower risk of hypoglycemia, compared to glipizide. READ THIS NEXT:Aptensio X...